TTI-621 (SIRPαFc), a CD47-blocking cancer immunotherapeutic, triggers phagocytosis of lymphoma cells by multiple polarized macrophage subsets.

by Gloria H Y Lin, Vien Chai, Vivian Lee, Karen Dodge, Tran Truong, Mark Wong, Lisa D Johnson, Emma Linderoth, Xinli Pang, Jeff Winston, Penka S Petrova, Robert A Uger, Natasja N Viller
Published 2017-01-01